Nachrichten & Blogs

L’un des plus grands défis dans le traitement du cancer est que chaque cancer se comporte différemment. Nombreuses questions se posent telles que : Va-t-il croître rapidement ou lentement? Va-t-il se propager à d’autres organes ou non? Pourrait-il revenir après le traitement ?

We are excited to announce that the EndoPredict test, a leading prognostic tool for early-stage breast cancer, is now available in Australia with NATA accreditation.

Eine der größten Herausforderungen bei der Behandlung von Krebs ist, dass sich jeder Krebs anders verhalten kann. Wird er schnell oder langsam wachsen? Wird er sich auf andere Organe ausbreiten oder nicht? Könnte er nach der Therapie wiederkommen?

One of the biggest challenges in treating cancer is that each one can behave differently to the next. Will it grow fast, or slow? Will it spread to other organs or not? Might it come back after therapy?

We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer”.

The National Institute for Health and Care Excellence (NICE) in the UK has issued a new guidance, endorsing the use of EndoPredict, a cutting-edge diagnostic tool to support healthcare providers to make decisions on the use of chemotherapy in patients with lymph node positive early ER+ HER2- breast cancer.

Prognostic value of EndoPredict test in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial. We are excited to share findings from a recently published analysis exploring the prognostic value of EndoPredict using prospectively collected data from node-positive ER+ HER2- breast cancer patients screened for the randomized, double-blind, phase III UNIRAD trial.

We are pleased to share the latest insights from the ESMO Clinical Practice Guideline for the diagnosis, treatment, and follow-up of early breast cancer, particularly focusing on the significance of genomic testing in estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) early breast cancer.​

Two prospective real-world studies presented at SABCS show EndoPredict accurately guides decisions on chemotherapy in ER+, HER2- breast cancer.

we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer.

New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy, regardless of nodal status.

We are pleased to announce new data from the prospective EXET trial involving EndoPredict, our prognostic and predictive test for ER positive, HER2 negative early-stage breast cancer.